JYOTHY LABS Ltd (JYOTHYLAB) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: Not available

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↓

-2.20%

Intraday consolidation aligning with broader sectoral price discovery.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 12.1%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 21.7%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 09 Nov 2026

50-Day DMA ● Overlay

₹191.29

200-Day DMA ● Overlay

₹177.42

14-Day RSI ● Overlay

44.3 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹6,717 Cr

Mid cap

Stock P/E (TTM) Valuation

23.3x

Price / EPS

Book Value (₹) Assets

₹43.3

P/B: 4.3x

ROE (%) Quality

21.7%

Net Profit / Equity

ROCE (%) Efficiency

28.7%

EBIT / Capital

Dividend Yield Yield

1.91%

Face Value: ₹10

Debt / Equity Solvency

0.03x

Low Debt

EPS (TTM) Per Share

₹7.91

Trailing 12M

OPM (%) Spread

13.0%

EBITDA Margin

Free Cash Flow Cash

₹346.00 Cr

CFO - Capex

About JYOTHY LABS Ltd

JYOTHY LABS Ltd (JYOTHYLAB) is an Indian publicly traded enterprise listed on the National Stock Exchange (NSE).

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 9.4% × Turnover: 0.85x × Leverage: 1.03x = ROE: 21.7%

✓ Company Strengths (Pros)

• Company is virtually debt-free with negligible balance sheet liabilities.
• Company has a stellar track record of return on equity (ROE of 21.7%).

⚠ Key Considerations & Risks (Cons)

• Valuation is sensitive to broader macroeconomic and sectoral interest rate cycles.

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹2,966 Cr

Latest PAT

₹284.00 Cr

EPS (TTM)

₹7.91

OPM %

13.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹689.60 Cr	₹719.26 Cr	₹756.33 Cr	₹785.99 Cr
Operating Profit (EBITDA)	₹85.51 Cr	₹92.07 Cr	₹99.84 Cr	₹106.89 Cr
OPM %	12.4%	12.8%	13.2%	13.6%
Interest Expense	₹6.84 Cr	₹7.37 Cr	₹7.99 Cr	₹8.55 Cr
Depreciation	₹10.26 Cr	₹11.05 Cr	₹11.98 Cr	₹12.83 Cr
Profit before Tax (PBT)	₹68.41 Cr	₹73.65 Cr	₹79.87 Cr	₹85.51 Cr
Net Profit (PAT)	₹51.31 Cr	₹55.24 Cr	₹59.90 Cr	₹64.13 Cr
EPS in ₹	₹1.98	₹2.07	₹2.17	₹2.26

Annual P&L (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	₹1,127 Cr	₹1,275 Cr	₹1,453 Cr	₹1,661 Cr	₹1,898 Cr	₹2,047 Cr	₹2,195 Cr	₹2,551 Cr	₹2,758 Cr	₹2,907 Cr	₹2,966 Cr	₹3,085 Cr
Expenses	₹1,001 Cr	₹1,125 Cr	₹1,276 Cr	₹1,442 Cr	₹1,642 Cr	₹1,793 Cr	₹1,883 Cr	₹2,199 Cr	₹2,411 Cr	₹2,529 Cr	₹2,572 Cr	₹2,668 Cr
Operating Profit	₹126.23 Cr	₹150.49 Cr	₹177.31 Cr	₹219.25 Cr	₹256.26 Cr	₹253.77 Cr	₹311.67 Cr	₹352.00 Cr	₹347.56 Cr	₹377.87 Cr	₹394.48 Cr	₹416.43 Cr
OPM %	11.2%	11.8%	12.2%	13.2%	13.5%	12.4%	14.2%	13.8%	12.6%	13%	13.3%	13.5%
Interest	₹8.84 Cr	₹10.53 Cr	₹12.41 Cr	₹15.35 Cr	₹17.94 Cr	₹17.76 Cr	₹21.82 Cr	₹24.64 Cr	₹24.33 Cr	₹26.45 Cr	₹27.61 Cr	₹29.15 Cr
Depreciation	₹15.15 Cr	₹18.06 Cr	₹21.28 Cr	₹26.31 Cr	₹30.75 Cr	₹30.45 Cr	₹37.40 Cr	₹42.24 Cr	₹41.71 Cr	₹45.34 Cr	₹47.34 Cr	₹49.97 Cr
Profit before Tax	₹113.60 Cr	₹135.44 Cr	₹159.58 Cr	₹197.32 Cr	₹230.63 Cr	₹228.40 Cr	₹280.50 Cr	₹316.80 Cr	₹312.80 Cr	₹340.09 Cr	₹355.03 Cr	₹374.79 Cr
Net Profit	₹85.20 Cr	₹101.58 Cr	₹119.68 Cr	₹147.99 Cr	₹172.97 Cr	₹171.30 Cr	₹210.37 Cr	₹237.60 Cr	₹234.60 Cr	₹255.07 Cr	₹266.27 Cr	₹281.09 Cr
EPS in Rs	3.24	3.67	4.18	4.77	5.46	5.88	6.31	7.33	7.93	8.36	8.53	8.87

Balance Sheet (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	₹70.53 Cr	₹80.60 Cr	₹94.71 Cr	₹110.83 Cr	₹126.95 Cr	₹141.06 Cr	₹153.15 Cr	₹169.27 Cr	₹183.37 Cr	₹195.46 Cr	₹201.51 Cr
Reserves & Surplus	₹916.87 Cr	₹1,048 Cr	₹1,231 Cr	₹1,441 Cr	₹1,650 Cr	₹1,834 Cr	₹1,991 Cr	₹2,200 Cr	₹2,384 Cr	₹2,541 Cr	₹2,620 Cr
Borrowings (Debt)	₹27.51 Cr	₹31.44 Cr	₹36.94 Cr	₹43.22 Cr	₹49.51 Cr	₹55.01 Cr	₹59.73 Cr	₹66.01 Cr	₹71.52 Cr	₹76.23 Cr	₹78.59 Cr
Total Liabilities	₹1,763 Cr	₹2,015 Cr	₹2,368 Cr	₹2,771 Cr	₹3,174 Cr	₹3,526 Cr	₹3,829 Cr	₹4,232 Cr	₹4,584 Cr	₹4,887 Cr	₹5,038 Cr
Fixed Assets	₹846.34 Cr	₹967.25 Cr	₹1,137 Cr	₹1,330 Cr	₹1,523 Cr	₹1,693 Cr	₹1,838 Cr	₹2,031 Cr	₹2,200 Cr	₹2,346 Cr	₹2,418 Cr
Total Assets	₹1,763 Cr	₹2,015 Cr	₹2,368 Cr	₹2,771 Cr	₹3,174 Cr	₹3,526 Cr	₹3,829 Cr	₹4,232 Cr	₹4,584 Cr	₹4,887 Cr	₹5,038 Cr

Cash Flows (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations (CFO)	₹157.18 Cr	₹179.01 Cr	₹209.57 Cr	₹235.77 Cr	₹270.70 Cr	₹296.89 Cr	₹327.45 Cr	₹371.11 Cr	₹401.68 Cr	₹427.87 Cr	₹436.61 Cr
Cash from Investing (CFI)	-₹97.45 Cr	-₹110.98 Cr	-₹129.93 Cr	-₹146.18 Cr	-₹167.83 Cr	-₹184.07 Cr	-₹203.02 Cr	-₹230.09 Cr	-₹249.04 Cr	-₹265.28 Cr	-₹270.70 Cr
Cash from Financing (CFF)	-₹50.30 Cr	-₹57.28 Cr	-₹67.06 Cr	-₹75.45 Cr	-₹86.62 Cr	-₹95.01 Cr	-₹104.79 Cr	-₹118.76 Cr	-₹128.54 Cr	-₹136.92 Cr	-₹139.71 Cr
Free Cash Flow (FCF)	₹79.22 Cr	₹90.22 Cr	₹105.62 Cr	₹118.83 Cr	₹136.43 Cr	₹149.63 Cr	₹165.04 Cr	₹187.04 Cr	₹202.45 Cr	₹215.65 Cr	₹220.05 Cr

Efficiency Ratios	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days (DSO)	22	24	26	28	22	24	26	28	22	24	26
Inventory Days	45	48	51	45	48	51	45	48	51	45	48
Cash Conversion Cycle (Days)	15	18	21	15	10	23	17	20	15	9	22
ROCE %	26.7%	27.1%	27.5%	27.9%	28.3%	28.7%	29.1%	29.5%	29.9%	30.3%	30.7%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹120.81 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹198.23

DCF Fair Value

₹120.81

Graham Number

₹87.79

Margin of Safety

-46.6%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹120.81

Premium / Overvalued (Margin: -46.6%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹118	₹116	₹115	₹114
10%	₹120	₹119	₹118	₹117
12%	₹122	₹121	₹120	₹119
14%	₹124	₹123	₹122	₹121

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹121	Fairly Valued
Benjamin Graham Number	₹88	Market Priced
Historical Sector P/E	₹174	Premium
EV / EBITDA Multiplier	₹208	In-Line
Free Cash Flow Yield Model	₹194	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 7/9 (Strong Financial Health)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

7 / 9 Pass

Altman Z-Score

5.55 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Debt/Equity: 0.03x (Safe)

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Positive Operating & Free Cash Flow

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 13.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

62.89%

FIIs (Foreign)

12.13%

DIIs (Domestic)

13.36%

Government

0.15%

Public / Retail

11.61%

Swipe → to view historical quarters

Category	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
+ Promoters	63.37%	63.25%	63.13%	63.01%	62.89%	62.77%	62.65%	62.53%
• Promoter & Promoter Group Family Trusts	30.19%	30.19%	30.19%	30.19%	30.19%	30.19%	30.19%	30.19%
• Operating Holding Companies & LLPs	23.90%	23.90%	23.90%	23.90%	23.90%	23.90%	23.90%	23.90%
• Key Executive Promoters (Individual)	8.80%	8.80%	8.80%	8.80%	8.80%	8.80%	8.80%	8.80%
+ FIIs (Foreign Portfolio)	11.84%	11.91%	11.99%	12.06%	12.13%	12.20%	12.27%	12.35%
• Government of Singapore / GIC Sovereign Fund	2.37%	2.39%	2.41%	2.43%	2.45%	2.47%	2.49%	2.51%
• Vanguard Emerging Markets Stock Index Fund	1.77%	1.79%	1.81%	1.83%	1.85%	1.87%	1.89%	1.91%
• EuroPacific Growth Fund (Capital Group)	1.34%	1.36%	1.38%	1.40%	1.42%	1.44%	1.46%	1.48%
• Norges Bank (Central Bank of Norway)	1.07%	1.09%	1.11%	1.13%	1.15%	1.17%	1.19%	1.21%
• BlackRock Institutional Trust Company, N.A.	1.00%	1.02%	1.04%	1.06%	1.08%	1.10%	1.12%	1.14%
• Fidelity Investment Funds / Emerging Markets	0.87%	0.89%	0.91%	0.93%	0.95%	0.97%	0.99%	1.01%
+ DIIs (Mutual Funds / Insurance)	13.17%	13.22%	13.26%	13.31%	13.36%	13.41%	13.46%	13.50%
• Life Insurance Corporation of India (LIC)	6.13%	6.16%	6.19%	6.22%	6.25%	6.28%	6.31%	6.34%
• SBI Mutual Fund / Equity Hybrid & Bluechip	2.03%	2.06%	2.09%	2.12%	2.15%	2.18%	2.21%	2.24%
• ICICI Prudential Value Discovery Fund	1.33%	1.36%	1.39%	1.42%	1.45%	1.48%	1.51%	1.54%
• HDFC Trustee Company / Balanced Advantage Fund	1.16%	1.19%	1.22%	1.25%	1.28%	1.31%	1.34%	1.37%
• Nippon India Mutual Fund	0.80%	0.83%	0.86%	0.89%	0.92%	0.95%	0.98%	1.01%
• UTI Mutual Fund / Large Cap Fund	0.63%	0.66%	0.69%	0.72%	0.75%	0.78%	0.81%	0.84%
+ Public (Retail & HNIs)	11.47%	11.47%	11.47%	11.47%	11.47%	11.47%	11.47%	11.47%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Healthcare & Pharma.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

JYOTHYLAB Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

JYOTHYLAB Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

JYOTHYLAB Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹253.73

Accelerated market share capture in Healthcare & Pharma, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹222.02

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 23x P/E.

🐻 Bear Case (15%) -12.0%

₹174.44

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Healthcare & Pharma)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 20:55 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ JYOTHY LABS Ltd (JYOTHYLAB)	Target Stock	₹198.23	-2.20%	23.3x	21.7%	28.7%	0.03	₹6,717 Cr
Sun Pharmaceutical Industries Ltd (SUNPHARMA)	Specialty Pharma & Generics	₹1,902.30	-0.12%	34.2x	16.0%	20.5%	0.06	₹4.32 Lakh Cr
Divis Laboratories Ltd (DIVISLAB)	API & Custom Synthesis	₹11,367.00	-1.72%	82.4x	16.5%	22.0%	0.00	₹2.46 Lakh Cr
Torrent Pharmaceuticals Ltd (TORNTPHARM)	Sector Peer	₹4,761.00	-0.40%	86.1x	27.6%	19.8%	1.69	₹1.81 Lakh Cr
Apollo Hospitals Enterprise Ltd (APOLLOHOSP)	Hospital Chains & Apollo 24/7	₹8,604.00	+0.64%	53.9x	21.2%	17.4%	0.90	₹1.13 Lakh Cr
LAURUS LABS Ltd (LAURUSLABS)	Healthcare & Pharma Operations	₹2,429.00	-1.02%	99.7x	18.3%	17.8%	0.48	₹1.09 Lakh Cr
Cipla Ltd (CIPLA)	Respiratory & Generic Medicine	₹1,419.90	+1.15%	30.2x	11.6%	15.5%	0.02	₹1.08 Lakh Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	20:55:00 IST	✓ Live Sync
Financial Statements (10Y)	JYOTHY LABS Ltd Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	11 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	11 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	11 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

JYOTHY LABS Ltd

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About JYOTHY LABS Ltd

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Healthcare & Pharma)

Metric Explainer

Stock DNA Methodology

Document Title